Alzheimer Disease, Cognitive Impairment
Conditions
Brief summary
This study explores the safety, pharmacodynamics and pharmacokinetics of THN201 a combination of donepezil and mefloquine to improve cognitive function in healthy male volunteers after impairment by a scopolamine challenge.
Detailed description
This is a double-blind, 3-arm, parallel group study of 15 days duration including a scopolamine challenge at D15. Healthy male subjects will receive daily doses of THN201 (donepezil 5 mg and mefloquine), donepezil 5 mg or placebo and one subcutaneous injection of scopolamine 0.5 mg on D15. Cognitive function, EEG and P300 will be assessed at baseline and before and after scopolamine challenge at D15. A final safety evaluation will be performed 2 weeks after the end of the treatment period. Pharmacokinetic assessments will be performed to obtain a time/concentration profile of donepezil and mefloquine.
Interventions
DRUGTHN 201
THN 201: Donepezil 5 mg and Mefloquine 10 mg/d
DRUGDonepezil
Donepezil 5 mg/d and Mefloquine placebo
DRUGPlacebo
Donepezil placebo and Mefloquine placebo
Sponsors
Theranexus
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* A body mass index (BMI), calculated as weight in kg/(height in m)², from 18 to 30 kg/m², inclusive * Healthy as determined by the investigator after a comprehensive clinical assessment based on medical history, physical examination, clinical laboratory test results, vital sign measurements, blood pressure (BP), heart rate (HR) and digital 12-lead ECG readings (all results should be normal or, if out of range, they should be non-clinically significant as determined by the investigator)
Exclusion criteria
* Any significant cardiovascular (e.g. heart failure), pulmonary (including asthma), hepatic, renal, respiratory (e.g. asthma), gastrointestinal, endocrine (e.g. diabetes, dyslipidaemia), immunologic, dermatological, haematological, neurologic, psychiatric disease, history of any clinically important drug allergy, systemic or presence of infectious disease. * Current suicide risk or history of suicide risk (C-SSRS baseline: yes answer to items 4 and/or 5). * Brain imaging (MRI) at screening showing anatomical or vascular abnormality of any type. * EEG examination at screening showing abnormal (epileptiform) activities. * Symptomatic hypotension, * Participants with, or with a history of cardiac arrhythmia or cardiac disease or a personal or family history of long QT syndrome or a family history of sudden death. * Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. * Antimalarial medicine intake or returning from a malaria-endemic area within the 12 last months before the first IMP administration. * Planning to visit a country requiring antimalarial chemoprophylaxis during the study period. * History of adverse reaction after a previous mefloquine intake. * Contraindication for the use of Aricept® or for one of its excipients. * Contraindication for the use of piperidine derivative compounds or for other cholinesterase inhibitors. * Contraindication for the use of Lariam® or for one of its excipients. * Contraindication for the use of scopolamine S.C. injection. * History or presence of drug or alcohol abuse (alcohol consumption \> 21 units / week).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pharmacodynamics: Cognitive function measured with the Cognitive Drug Research (CDR) test battery | 15 days | Main variable: Power of attention is the sum of the speed scores (msec) from three tests: Simple Reaction Time, Choice Reaction Time, and Digital Vigilance. Low values indicate better performance |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety Adverse events | 29 days | Number of subjects with spontaneously reported treatment related adverse events |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pharmacokinetics Plasma concentration of donepezil and mefloquine | 29 days | Time profile of plasma concentrations of donepezil and mefloquine |
| Pharmacodynamics measured by quantitative EEG (qEEG) | 15 days | Spectral analysis of absolute and/or relative amplitude in delta, theta, alpha, beta and gamma bands; |
| Pharmacodynamics measured by event related EEG potentials (P300) | 15 days | Auditory P300 parameters (amplitude, latency and AUC) |
Countries
France
Outcome results
None listed